These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34514998)

  • 21. The poliovirus receptor CD155 mediates cell-to-matrix contacts by specifically binding to vitronectin.
    Lange R; Peng X; Wimmer E; Lipp M; Bernhardt G
    Virology; 2001 Jul; 285(2):218-27. PubMed ID: 11437656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD155: A Multi-Functional Molecule in Tumor Progression.
    Molfetta R; Zitti B; Lecce M; Milito ND; Stabile H; Fionda C; Cippitelli M; Gismondi A; Santoni A; Paolini R
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of secreted CD155 isoforms.
    Baury B; Masson D; McDermott BM; Jarry A; Blottière HM; Blanchardie P; Laboisse CL; Lustenberger P; Racaniello VR; Denis MG
    Biochem Biophys Res Commun; 2003 Sep; 309(1):175-82. PubMed ID: 12943679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor intrinsic and extrinsic immune functions of CD155.
    O'Donnell JS; Madore J; Li XY; Smyth MJ
    Semin Cancer Biol; 2020 Oct; 65():189-196. PubMed ID: 31883911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics.
    Sloan KE; Stewart JK; Treloar AF; Matthews RT; Jay DG
    Cancer Res; 2005 Dec; 65(23):10930-7. PubMed ID: 16322240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
    Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
    Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4
    Kamrani A; Soltani-Zangbar MS; Shiri S; Yousefzadeh Y; Pourakbari R; Aghebati-Maleki L; Mehdizadeh A; Danaii S; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Motavalli R; Zolfaghari M; Haji-Fatahaliha M; Mahmoodpoor A; Ahmadian Heris J; Emdadi A; Yousefi M
    Immunol Invest; 2022 May; 51(4):1023-1038. PubMed ID: 33855917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of CD155/TIGIT expression in patients with colorectal cancer.
    Murakami D; Matsuda K; Iwamoto H; Mitani Y; Mizumoto Y; Nakamura Y; Matsuzaki I; Iwamoto R; Takahashi Y; Kojima F; Murata SI; Yamaue H
    PLoS One; 2022; 17(3):e0265908. PubMed ID: 35324958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD155 as an emerging target in tumor immunotherapy.
    Wu JW; Liu Y; Dai XJ; Liu HM; Zheng YC; Liu HM
    Int Immunopharmacol; 2024 Apr; 131():111896. PubMed ID: 38518596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 Nef-mediated downregulation of CD155 results in viral restriction by KIR2DL5+ NK cells.
    Fittje P; Hœlzemer A; Garcia-Beltran WF; Vollmers S; Niehrs A; Hagemann K; Martrus G; Körner C; Kirchhoff F; Sauter D; Altfeld M
    PLoS Pathog; 2022 Jun; 18(6):e1010572. PubMed ID: 35749424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains.
    Meyer D; Seth S; Albrecht J; Maier MK; du Pasquier L; Ravens I; Dreyer L; Burger R; Gramatzki M; Schwinzer R; Kremmer E; Foerster R; Bernhardt G
    J Biol Chem; 2009 Jan; 284(4):2235-44. PubMed ID: 19056733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CD155/poliovirus receptor enhances the proliferation of ras-mutated cells.
    Kono T; Imai Y; Yasuda S; Ohmori K; Fukui H; Ichikawa K; Tomita S; Imura J; Kuroda Y; Ueda Y; Fujimori T
    Int J Cancer; 2008 Jan; 122(2):317-24. PubMed ID: 17893876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
    Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
    Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poliovirus receptor CD155-targeted oncolysis of glioma.
    Merrill MK; Bernhardt G; Sampson JH; Wikstrand CJ; Bigner DD; Gromeier M
    Neuro Oncol; 2004 Jul; 6(3):208-17. PubMed ID: 15279713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor.
    Inoue T; Adachi K; Kawana K; Taguchi A; Nagamatsu T; Fujimoto A; Tomio K; Yamashita A; Eguchi S; Nishida H; Nakamura H; Sato M; Yoshida M; Arimoto T; Wada-Hiraike O; Oda K; Osuga Y; Fujii T
    Int J Oncol; 2016 Oct; 49(4):1297-304. PubMed ID: 27499237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
    Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.